Tolcapone increases maximum concentration of levodopa

No significant increase of the maximum concentration (Cmax) of levodopa after addition of catechol-O-methyltransferase inhibitor tolcapone occurred in previous pharmacokinetic studies predominantly on healthy volunteers. We compared pharmacokinetics of levodopa in plasma before and after addition of...

Full description

Saved in:
Bibliographic Details
Published inJournal of Neural Transmission Vol. 107; no. 1; pp. 113 - 119
Main Authors Müller, T., Woitalla, D., Schulz, D., Peters, S., Kuhn, W., Przuntek, H.
Format Journal Article
LanguageEnglish
Published Austria 01.01.2000
Subjects
Aged
Aged, 80 and over
Antiparkinson Agents - pharmacokinetics
Benzophenones - pharmacokinetics
Catechol O-Methyltransferase - blood
Catechol O-Methyltransferase Inhibitors
Female
Humans
Levodopa - pharmacokinetics
Male
Middle Aged
Nitrophenols
Parkinson Disease - drug therapy
Parkinson Disease - enzymology
Online AccessGet full text

Cover

More Information
Summary:No significant increase of the maximum concentration (Cmax) of levodopa after addition of catechol-O-methyltransferase inhibitor tolcapone occurred in previous pharmacokinetic studies predominantly on healthy volunteers. We compared pharmacokinetics of levodopa in plasma before and after addition of tolcapone in 13 treated parkinsonian subjects under standardized conditions. We found a significant increase of Cmax of levodopa after the addition of tolcapone. This may represent one cause for the occurrence of dyskinesia previously early in the course of treatment with tolcapone.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0300-9564
1435-1463
DOI:10.1007/s007020050010